Evidence map›Paper›PMID 42818120›Full record

ArticlebioRxiv : the preprint server for biology2026

Performance of Rilpivirine-Based Hydrophobic Tags and PROTACs Directed Against HIV-1 Reverse Transcriptase.

Ferdinand K Amanor, Garrett D Clements, Rabia Khurshid, Anna F Howard, Diana Soto Martinez, Courtney Barkley, Zhengrong Yang, Kabita Gyawali, John C Kappes, Robert C Reynolds and 3 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ferdinand K AmanorDepartment of Medicine, University of Alabama at Birmingham, AL, USA.ORCID 0000-0003-2455-3606
Garrett D ClementsDepartment of Chemistry and Biochemistry, The University of Alabama Tuscaloosa, AL, USA.ORCID 0009-0004-9664-1976
Rabia KhurshidDepartment of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami FL, USA.ORCID 0009-0005-7585-7740
Anna F HowardDepartment of Chemistry and Biochemistry, The University of Alabama Tuscaloosa, AL, USA.ORCID 0009-0005-4659-2827
Diana Soto MartinezDepartment of Chemistry and Biochemistry, The University of Alabama Tuscaloosa, AL, USA.ORCID 0009-0000-8968-6253
Courtney BarkleyDepartment of Medicine, University of Alabama at Birmingham, AL, USA.ORCID 0000-0002-6207-9995
Zhengrong YangDepartment of Biochemistry & Molecular Genetics, University of Alabama at Birmingham, AL, USA.ORCID 0000-0002-8981-9105
Kabita GyawaliDepartment of Chemistry and Biochemistry, The University of Alabama Tuscaloosa, AL, USA.ORCID 0000-0001-7562-8052
John C KappesDepartment of Medicine, University of Alabama at Birmingham, AL, USA.ORCID 0000-0002-7586-2815
Robert C ReynoldsDepartment of Medicine, University of Alabama at Birmingham, AL, USA.ORCID 0000-0001-9413-2247
Stephan C SchürerDepartment of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami FL, USA.ORCID 0000-0002-5615-5576
Timothy S SnowdenDepartment of Chemistry and Biochemistry, The University of Alabama Tuscaloosa, AL, USA.ORCID 0000-0002-6838-1220
Christina OchsenbauerDepartment of Medicine, University of Alabama at Birmingham, AL, USA.ORCID 0000-0003-1166-5879

Funding

A New Paradigm for HIV Treatment: Targeted Degradation of HIV Reverse Transcriptase via the Ubiquitin-Proteasome PathwayR21AI157362 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI REYNOLDS, ROBERT C · 2021 to 2022
$434k
NIAID NIH HHS R21 AI157362
6 · The paper itself

Abstract

We aimed to repurpose the non-nucleoside reverse transcriptase (RT) inhibitor (NNRTI) rilpivirine (RPV) as a targeted protein degrader (TPD) of HIV-1 RT. Structure-guided modeling identified a TPD bifunctional linker exit trajectory from RPV that threads the NNRTI entrance channel. Ten RPV analogs (RPV') with varied warhead-linker attachments retained RT inhibition and antiviral activity, guiding selection of an amide-linked connector for degrader construction. We synthesized Proteolysis Targeting Chimeras (PROTACs) designed to recruit CUL4

Indexed as

HIV-1Hydrophobic TagPROTACsReverse TranscriptaseTargeted Protein Degradation

Identifiers

PMID42818120
PMCPMC13622284

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.